{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T05:09:56Z","timestamp":1783487396516,"version":"3.55.0"},"reference-count":22,"publisher":"The Endocrine Society","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,1,1]]},"abstract":"<jats:sec>\n                  <jats:title>Context and Objective:<\/jats:title>\n                  <jats:p>The primary purpose of this study was to detect and quantify 3-iodothyronamine (T1AM), an endogenous biogenic amine related to thyroid hormone, in human blood.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Design:<\/jats:title>\n                  <jats:p>T1AM, total T3, and total T4 were assayed in serum by a novel HPLC tandem mass spectrometry assay, which has already been validated in animal investigations, and the results were related to standard clinical and laboratory variables.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Setting and Patients:<\/jats:title>\n                  <jats:p>The series included one healthy volunteer, 24 patients admitted to a cardiological ward, and 17 ambulatory patients suspected of thyroid disease, who underwent blood sampling at admission for routine diagnostic purposes. Seven patients were affected by type 2 diabetes, and six patients showed echocardiographic evidence of impaired left ventricular function.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Interventions:<\/jats:title>\n                  <jats:p>No intervention or any patient selection was performed.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Main Outcome Measures:<\/jats:title>\n                  <jats:p>serum T1AM, total and free T3 and T4, routine chemistry, routine hematology, and echocardiographic parameters were measured.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results:<\/jats:title>\n                  <jats:p>T1AM was detected in all samples, and its concentration averaged 0.219 \u00b1 0.012 pmol\/ml. The T1AM concentration was significantly correlated to total T4 (r = 0.654, P &amp;lt; 0.001), total T3 (r = 0.705, P &amp;lt; 0.001), glycated hemoglobin (r = 0.508, P = 0.013), brain natriuretic peptide (r = 0.543, P = 0.016), and \u03b3-glutamyl transpeptidase (r = 0.675, P &amp;lt; 0.001). In diabetic vs. nondiabetic patients T1AM concentration was significantly increased (0.232 \u00b1 0.014 vs. 0.203 \u00b1 0.006 pmol\/ml, P = 0.044), whereas no significant difference was observed in patients with cardiac dysfunction.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions:<\/jats:title>\n                  <jats:p>T1AM is an endogenous messenger that can be assayed in human blood. Our results are consistent with the hypothesis that circulating T1AM is produced from thyroid hormones and encourage further investigations on the potential role of T1AM in insulin resistance and heart failure.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1210\/jc.2011-1115","type":"journal-article","created":{"date-parts":[[2011,10,27]],"date-time":"2011-10-27T00:29:37Z","timestamp":1319675377000},"page":"E69-E74","source":"Crossref","is-referenced-by-count":52,"title":["Detection of 3-Iodothyronamine in Human Patients: A Preliminary Study"],"prefix":"10.1210","volume":"97","author":[{"given":"Elena","family":"Galli","sequence":"first","affiliation":[{"name":"Scuola Superiore S. Anna (E.G.), 56127 Pisa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maja","family":"Marchini","sequence":"additional","affiliation":[{"name":"Dipartimento di Scienze dell'Uomo e dell'Ambiente (M.M., A.S., R.Z.), 56126 Pisa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Saba","sequence":"additional","affiliation":[{"name":"Dipartimento di Scienze dell'Uomo e dell'Ambiente (M.M., A.S., R.Z.), 56126 Pisa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Berti","sequence":"additional","affiliation":[{"name":"Fondazione Gabriele Monasterio (S.B.), Ospedale del Cuore, 54100 Massa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Tonacchera","sequence":"additional","affiliation":[{"name":"Dipartimento di Endocrinologia (M.T., P.V.), University of Pisa, 56126 Pisa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Vitti","sequence":"additional","affiliation":[{"name":"Dipartimento di Endocrinologia (M.T., P.V.), University of Pisa, 56126 Pisa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas S.","family":"Scanlan","sequence":"additional","affiliation":[{"name":"Departments of Physiology and Pharmacology and Cell and Developmental Biology (T.S.S.), Oregon Health and Science University, Portland, Oregon 97239"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgio","family":"Iervasi","sequence":"additional","affiliation":[{"name":"Istituto di Fisiologia Clinica (G.I.), 56124 Pisa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo","family":"Zucchi","sequence":"additional","affiliation":[{"name":"Dipartimento di Scienze dell'Uomo e dell'Ambiente (M.M., A.S., R.Z.), 56126 Pisa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","reference":[{"key":"2020071615594648300_B1","first-page":"638","article-title":"3-Iodothyronamine is an endogenous and rapid-acting derivative of thyroid hormone.","volume-title":"Nat Med","author":"Scanlan","year":"2004"},{"key":"2020071615594648300_B2","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1021\/cb700057b","article-title":"Thyronamines inhibit plasma membrane and vescicular monoamine transport.","volume":"2","author":"Snead","year":"2007","journal-title":"ACS Chem Biol"},{"key":"2020071615594648300_B3","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.ejphar.2008.03.055","article-title":"Cardiac effects of trace amines: pharmacological characterization of trace amine associated receptors.","volume":"587","author":"Frascarelli","year":"2008","journal-title":"Eur J Pharmacol"},{"key":"2020071615594648300_B4","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.bbabio.2010.04.106","article-title":"3-Iodothyronamine favours IF1 release from F0F1 ATP synthase.","volume":"1797","author":"Cumero","year":"2010","journal-title":"Biochim Biophys Acta Bioenergetics"},{"key":"2020071615594648300_B5","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1039\/b926588k","article-title":"Transport of thyroid hormones is selectively inhibited by 3-iodothyronamine.","volume":"6","author":"Ianculescu","year":"2010","journal-title":"Mol BioSyst"},{"key":"2020071615594648300_B6","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1038\/sj.bjp.0706948","article-title":"Trace amine-associated receptors and their ligands.","volume":"149","author":"Zucchi","year":"2006","journal-title":"Br J Pharmacol"},{"key":"2020071615594648300_B7","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1039\/b926583j","article-title":"3-iodothyronamine (T1AM): a new chapter of thyroid hormone endocrinology?","volume":"6","author":"Ianculescu","year":"2010","journal-title":"Mol BioSyst"},{"key":"2020071615594648300_B8","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1210\/er.2009-0040","article-title":"Thyronamines\u2014past, present, and future.","volume":"32","author":"Piehl","year":"2011","journal-title":"Endocr Rev"},{"key":"2020071615594648300_B9","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1096\/fj.06-7474com","article-title":"Cardiac effects of 3-iodothyronamine: a new aminergic system modulating cardiac function.","volume":"21","author":"Chiellini","year":"2007","journal-title":"FASEB J"},{"key":"2020071615594648300_B10","doi-asserted-by":"crossref","first-page":"3082","DOI":"10.1111\/j.1582-4934.2009.00728.x","article-title":"Modulation of cardiac ionic homeostasis by 3-iodothyronamine","volume":"13","author":"Ghelardoni","year":"2009","journal-title":"J Cell Mol Med"},{"key":"2020071615594648300_B11","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s00360-007-0208-x","article-title":"3-Iodothyronamine: a novel hormone controlling the balance between glucose and lipid utilisation.","volume":"178","author":"Braulke","year":"2008","journal-title":"J Comp Physiol B"},{"key":"2020071615594648300_B12","first-page":"4034","article-title":"Probing cell type-specific functions of Gi in vivo identifies GPCR regulators of insulin secretion.","volume":"117","author":"Regard","year":"2007","journal-title":"J Clin Invest"},{"key":"2020071615594648300_B13","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1677\/JOE-09-0043","article-title":"Central effects of thyronamines on glucose metabolism in rats.","volume":"201","author":"Klieverik","year":"2009","journal-title":"J Endocrinol"},{"key":"2020071615594648300_B14","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1111\/j.1463-1326.2008.00935.x","article-title":"The thyroid hormone derivative 3-iodothyronamine increases food intake in rodents.","volume":"11","author":"Dhillo","year":"2009","journal-title":"Diabetes Obes Metab"},{"key":"2020071615594648300_B15","article-title":"3-Iodothyronamine (T1AM) causes weight loss in mice via reduction in food consumption","author":"Hettinger","year":"2010"},{"key":"2020071615594648300_B16","first-page":"A60","article-title":"Development and validation of an isotope dilution tandem mass spectrometry method for simultaneous quantification of 3-iodothyronamine, thyroxine, triiodothyronine, and 3,3\u2032-diiodo-l-thyronine.","volume":"56","author":"Gu","year":"2010","journal-title":"Clin Chem"},{"key":"2020071615594648300_B17","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1677\/JOE-10-0060","article-title":"An online solid-phase extraction-liquid chromatography-tandem mass spectrometry method to study the presence of thyronamines in plasma and tissue and their putative conversion from 13C6-thyroxine.","volume":"206","author":"Ackermans","year":"2010","journal-title":"J Endocrinol"},{"key":"2020071615594648300_B18","doi-asserted-by":"crossref","first-page":"5063","DOI":"10.1210\/en.2010-0491","article-title":"Tissue distribution and cardiac metabolism of 3-iodothyronamine.","volume":"151","author":"Saba","year":"2010","journal-title":"Endocrinology"},{"key":"2020071615594648300_B19","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1016\/j.clinbiochem.2008.04.007","article-title":"Reference intervals for TSH and thyroid hormones are mainly affected by age, body mass index and number of blood leucocytes, but hardly by gender and thyroid autoantibodies during the first decades of life.","volume":"41","author":"Kratzsch","year":"2008","journal-title":"Clin Biochem"},{"key":"2020071615594648300_B20","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1210\/jc.2010-2680","article-title":"Evidence for extrathyroidal formation of 3-iodothyronamine in humans as provided by a novel monoclonal antibody-based chemiluminescent serum immunoassay.","volume":"96","author":"Hoefig","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071615594648300_B21","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1210\/jc.2011-0688","article-title":"Endogenous 3-iodothyronamine (T1AM): more than we bargained for.","volume":"96","author":"Scanlan","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071615594648300_B22","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.cca.2009.11.016","article-title":"Comparison of FT4 with logTSH on the Abbott Architect ci8200: pediatric reference intervals for free thyroxine and thyroid-stimulating hormone.","volume":"411","author":"Soldin","year":"2010","journal-title":"Clin Chim Acta"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/97\/1\/E69\/10747085\/jcem0E69.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/97\/1\/E69\/10747085\/jcem0E69.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,17]],"date-time":"2020-07-17T03:04:24Z","timestamp":1594955064000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/97\/1\/E69\/2833725"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,1,1]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,1,1]]}},"URL":"https:\/\/doi.org\/10.1210\/jc.2011-1115","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,1,1]]}}}